Therefore, it would be important to investigate whether MHC class I-restricted CD4+ T cells are sufficient to support anti-tumor immunity, or whether physiological MHC class II-restricted CD4+ T cells would play distinct roles in the presence or absence of MHC class II+ antigen-presenting cells. The gene discussed is CD4; the disease is neoplasm.